- Trials with a EudraCT protocol (21)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (9)
21 result(s) found for: Candidemia.
Displaying page 1 of 2.
EudraCT Number: 2015-005599-51 | Sponsor Protocol Number: CD101.IV.2.03 | Start Date*: 2016-09-26 | |||||||||||
Sponsor Name:Cidara Therapeutics Inc. | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-blind Study of the Safety, Tolerability, and Efficacy of CD101 Injection vs Intravenous Caspofungin Followed By Oral Fluconazole Step-down in the Treatmen... | |||||||||||||
Medical condition: Candidemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) GR (Completed) HU (Completed) BG (Completed) BE (Completed) IT (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003571-56 | Sponsor Protocol Number: APX001-201 | Start Date*: 2018-12-17 | |||||||||||
Sponsor Name:Amplyx Pharmaceuticals, Inc. | |||||||||||||
Full Title: An Open-Label Study to Evaluate the Efficacy and Safety of APX001 in Non-Neutropenic Patients with Candidemia, with or without Invasive Candidiasis, Inclusive of Patients with Suspected Resistance ... | |||||||||||||
Medical condition: Treatment of non-neutropenic subjects with candidemia – inclusive of those subjects with suspected or confirmed antifungal-resistant candidemia with or without invasive candidiasis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000648-32 | Sponsor Protocol Number: SCY-078-302 | Start Date*: 2023-03-31 | ||||||||||||||||
Sponsor Name:SCYNEXIS, Inc. | ||||||||||||||||||
Full Title: A Phase 3, Multicenter, Prospective, Randomized, Double-blind Study of Two Treatment Regimens for Candidemia and/or Invasive Candidiasis: Intravenous Echinocandin followed by Oral Ibrexafungerp ver... | ||||||||||||||||||
Medical condition: Invasive Candidiasis/ Candidemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GR (Trial now transitioned) FR (Trial now transitioned) ES (Temporarily Halted) BE (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003204-13 | Sponsor Protocol Number: 74527 | Start Date*: 2021-11-15 |
Sponsor Name:Radboudumc | ||
Full Title: Safety and Efficacy of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Candidemia | ||
Medical condition: Candidemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) GR (Trial now transitioned) RO (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2006-003951-18 | Sponsor Protocol Number: WSA-CS-008 | Start Date*: 2007-05-29 | |||||||||||
Sponsor Name:Astellas Global Pharma Development, Inc. | |||||||||||||
Full Title: A phase III, double-blind, randomized study to evaluate the safety and efficacy of BAL8557 versus a Caspofungin followed by Voriconazole regimen in the treatment of candidemia and other invasive Ca... | |||||||||||||
Medical condition: Treatment of Candidemia and other invasive Candida infections | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) HU (Completed) ES (Completed) NL (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-004854-97 | Sponsor Protocol Number: A8851019 | Start Date*: 2008-01-15 | |||||||||||
Sponsor Name:Pfizer Ltd | |||||||||||||
Full Title: OPEN-LABEL, NON-COMPARATIVE, STUDY OF INTRAVENOUS ANIDULAFUNGIN, FOLLOWED OPTIONALLY BY ORAL VORICONAZOLE OR FLUCONAZOLE THERAPY, FOR TREATMENT OF DOCUMENTED CANDIDEMIA/INVASIVE CANDIDIASIS IN INTE... | |||||||||||||
Medical condition: CANDIDAEMIA/INVASIVE CANDIDIASIS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) FR (Completed) BE (Completed) PT (Completed) NL (Completed) IT (Completed) SK (Completed) PL (Completed) CZ (Completed) DK (Completed) HU (Completed) DE (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-014600-66 | Sponsor Protocol Number: IFN-gamma 001 | Start Date*: 2010-08-10 | ||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:University Medical Center Nijmegen | ||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A multicentre, prospective, randomized open-label pilot study to assess the feasibility and preliminary efficacy of interferon gamma in combination with Anidulafungin for the treatment of candidemia | ||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Candida bloodstream infections/ candidemia | ||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2004-001491-39 | Sponsor Protocol Number: 03-0-192 | Start Date*: 2005-02-16 | |||||||||||
Sponsor Name:Astellas Pharma US, Inc. | |||||||||||||
Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, COMPARATIVE STUDY OF MICAFUNGIN (FK463) VERSUS CASPOFUNGIN AS ANTIFUNGAL TREATMENT IN PATIENTS WITH INVASIVE CANDIDIASIS OR CANDIDEMIA | |||||||||||||
Medical condition: Invasive candidiasis or candidemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) GB (Completed) BE (Completed) AT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012848-16 | Sponsor Protocol Number: A1501085 | Start Date*: 2010-04-28 | |||||||||||||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017, USA | |||||||||||||||||||||||
Full Title: A PROSPECTIVE, OPEN-LABEL, NON-COMPARATIVE STUDY TO ASSESS THE SAFETY, TOLERABILITY AND EFFICACY OF VORICONAZOLE FOR THE PRIMARY AND SALVAGE TREATMENT OF INVASIVE CANDIDIASIS, CANDIDEMIA, AND ESOPH... | |||||||||||||||||||||||
Medical condition: Invasive candidiasis, including candidemia (ICC), and esophageal candidiasis (EC) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) HU (Prematurely Ended) SK (Completed) CZ (Prematurely Ended) BG (Completed) RO (Completed) Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-004150-32 | Sponsor Protocol Number: A8851008 | Start Date*: 2008-11-18 | |||||||||||
Sponsor Name:Pfizer, Spain | |||||||||||||
Full Title: ESTUDIO PROSPECTIVO ABIERTO PARA EVALUAR LA FARMACOCINÉTICA, LA SEGURIDAD Y LA EFICACIA DE LA ANIDULAFUNGINA EN EL TRATAMIENTO DE NIÑOS Y ADOLESCENTES CON CANDIDIASIS INVASIVA, INCLUIDA LA CANDIDEM... | |||||||||||||
Medical condition: CANDIDIASIS INVASIVA, INCLUIDA CANDIDEMIA | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) DE (Completed) FR (Completed) PT (Completed) IT (Completed) GR (Completed) Outside EU/EEA GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002630-21 | Sponsor Protocol Number: CD101.IV.3.05 | Start Date*: 2019-01-10 | ||||||||||||||||
Sponsor Name:Cidara Therapeutics Inc. | ||||||||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection versus Intravenous Caspofungin Followed by Optional Oral Fluconazole Step-down in the... | ||||||||||||||||||
Medical condition: Candidemia; invasive candidiasis. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BG (Completed) DE (Completed) GR (Completed) FR (Completed) BE (Completed) IT (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000607-15 | Sponsor Protocol Number: GS-IT-131-0177 | Start Date*: 2007-12-06 | |||||||||||
Sponsor Name:GILEAD SCIENCES S.R.L. | |||||||||||||
Full Title: Phase II pilot multicenter study on efficacy and safety of liposomal amphotericin B (AmBisome) at 2 mg/kg/day in the treatment of candidemia and invasive candidiasis in nonneutropenic patients | |||||||||||||
Medical condition: CANDIDEMIA AND INVASIVE CANDIDIASIS | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000197-11 | Sponsor Protocol Number: A1501067 | Start Date*: 2017-03-15 |
Sponsor Name:Pfizer Inc. | ||
Full Title: Post Marketing Surveillance Study To Evaluate The Safety And Efficacy Of Vfend® IV | ||
Medical condition: Patients diagnosed as ‘invasive aspergillosis’, ‘serious fungal infections caused by Scedosporium apiospermum (asexual form of Pseudallescheria boydii) and Fusarium spp. including Fusarium solani i... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2004-004266-32 | Sponsor Protocol Number: 228/05 | Start Date*: 2006-06-12 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: THE USE OF CASPOFUNGIN(CANCIDAS) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCES AND CONCOMITANT CANDIDEMIA | |||||||||||||
Medical condition: CANDIDEMIA IN HEMATOLOGICAL MALIGNANCIES | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000780-24 | Sponsor Protocol Number: 9463-CL-2303 | Start Date*: 2012-07-24 |
Sponsor Name:Astellas Pharma Global Development, Inc. | ||
Full Title: A Phase 3, Randomized, Double-Blind, Multi-Center Study to Compare the Efficacy and Safety of Micafungin Versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis | ||
Medical condition: Neonatal Candidiasis | ||
Disease: | ||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: GR (Completed) HU (Completed) BG (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-005003-33 | Sponsor Protocol Number: WSA-CS-003 | Start Date*: 2008-06-26 | |||||||||||
Sponsor Name:Astellas Global Pharma Development, Inc | |||||||||||||
Full Title: Open label study of isavuconazole in the treatment of patients with aspergillosis and renal impairment or of patients with invasive fungal disease caused by rare moulds, yeasts or dimorphic fungi. | |||||||||||||
Medical condition: Invasive fungal disease caused by Aspergillus species in patients with renal impairment as well as disease caused by rare moulds, yeasts or dimorphic fungi. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) HU (Completed) CZ (Prematurely Ended) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004910-27 | Sponsor Protocol Number: MK-0991-074 | Start Date*: 2015-02-24 |
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | ||
Full Title: A Multicenter, Noncomparative, Open-label Study to Estimate the Safety, Efficacy, and Pharmacokinetics of MK-0991 (Caspofungin) in Japanese Children and Adolescents with Documented Candida or Asp... | ||
Medical condition: Candida or Aspergillus Infections | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2004-000424-32 | Sponsor Protocol Number: 045 | Start Date*: 2004-09-23 |
Sponsor Name:Merck Sharp & Dohme BV | ||
Full Title: A Multicenter, Open, Noncomparative Study to Estimate the Safety, Tolerability, and Efficacy of Caspofungin Acetate in the Treatment of Adults with Invasive Candida Infections (Excluding Patients w... | ||
Medical condition: Non-Blood Invasive Candidiasis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000381-29 | Sponsor Protocol Number: SCY-078-301 | Start Date*: 2017-07-17 |
Sponsor Name:SCYNEXIS, Inc. | ||
Full Title: Open-Label Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients with Fungal Diseases that are Refractory to, Resistant to or Intolerant of Standard Antifungal Treatment (FURI) | ||
Medical condition: Patients > 18 years of age with a documented invasive and/or severe fungal disease that has been intolerant, resistant or refractory (rIFI) to Standard of Care (SoC) antifungal treatment. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) ES (Ongoing) GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2008-005277-35 | Sponsor Protocol Number: A8851021 | Start Date*: 2009-02-26 | |||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: EFFICACY AND SAFETY OF ERAXIS™/ECALTA® (ANIDULAFUNGIN) COMPARED TO CANCIDAS® (CASPOFUNGIN) IN NEUTROPENIC PATIENTSWITH INVASIVE CANDIDA INFECTION | |||||||||||||
Medical condition: INVASIVE CANDIDIA INFECTIONS | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) IE (Prematurely Ended) SK (Prematurely Ended) FR (Completed) IT (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
